Project Grant R01AI187899
Award Date
7/18/25
Completion Date
6/30/29
Dollars Obligated
$3.1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $208,575 to develop an ionic liquid-based nanoemulsion containing a combination of antiretroviral drugs for the oral and transdermal treatment of HIV infection. The goal is to improve the oral bioavailability and skin permeability of the integrase inhibitor dolutegravir and the non-nucleoside reverse...
This Project Grant award of $438,500 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop new tools to facilitate drug discovery for pathogen proteasomes. The funded project at the University of California, San Diego aims to address two key bottlenecks in advancing research on parasite proteasomes - the difficulty in isolating and purifying parasite 20S proteasome enzymes,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $490,788 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF). The grant, titled "Quantifying Genomic and Pharmacometabolomic Differences in Antiretroviral Exposure in MACS/WIHS Combined Cohort Study", aims to identify genetic and metabolic factors that influence the plasma concentrations and associated...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop an innovative proteoliposome-based delivery system for therapeutic and bioactive cargo. The $213,284 award will fund research to repurpose viral fusion machinery, including proteins from influenza, Nipah virus, and SARS-CoV-2, to improve cellular uptake and targeted delivery of user-defined cargo. The...
This Project Grant award of $285,816 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research to enhance understanding of ADP-ribosylation (ADPR) and its role in HIV-1 latency and reactivation. The awardee, The Regents of the University of California, San Francisco, will conduct biochemical, proteomic, and cellular assays to identify global proteomic changes to ADPR during HIV-1 latency and reactivation,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $3,194,992 to the University of California, San Diego (UC San Diego) to conduct research on the roles and regulation of tissue-resident CD8 T cells during a persistent viral infection. The key objectives are to: (1) evaluate the role of tissue-resident CD8 T cells in intestinal hyper-permeability and colitis during a sustained viral...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $910,905.00 to the Scripps Research Institute to advance HIV vaccine development using a lipid nanodisc platform. The key objectives are to: Solve the structures of engineered transmembrane HIV envelope (Env) proteins incorporated into lipid nanodiscs in complex with broadly neutralizing antibodies targeting the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $506,000.00 to the Scripps Research Institute to develop high-throughput technologies for generating and screening small interfering RNA (siRNA)-peptide conjugates. The goal is to improve the delivery efficiency and overcome key bottlenecks of cellular uptake, endosomal escape, and siRNA activation for antiviral...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,248,576 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis. The grant, awarded on July 25, 2025, will fund research to understand the cross-protective efficacy of the recently FDA-approved IXCHIQ live attenuated chikungunya virus vaccine against other alphavirus species, assess the vaccine's infectivity and transmissibility in mosquitoes, and...
The federal Project Grant award R21AI185033 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of the APOBEC3B enzyme in the innate immune response against RNA viruses such as SARS-CoV-2, HIV-1, and Hepatitis B. The $228,435 award, effective January 2, 2025 through December 31, 2026, will fund research at the University of California, Irvine to identify novel...